JAK1/2 Inhibitors Linked to Lymphoma Risk in Myelofibrosis JAK1/2 Inhibitors Linked to Lymphoma Risk in Myelofibrosis

New data show that the use of JAK1/2 inhibitors, the only FDA-approved therapies for myeloproliferative neoplasms, is associated with a risk for lymphoma.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news